Resultados de la búsqueda 111-120 of 8462 for fsa eligible

1. Cirugía - Ensayos clínicos - Mayo Clinic

   Eligible patients with surgically accessible latent tumors desiring surgical resection will be enrolled to prospectively track short- and long-term outcomes.

2. Mayo Clinic Physician Update - June 2023

   Page 1.

3. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

4. Hematología - Ensayos clínicos - Mayo Clinic

   Rochester, Minn., Jacksonville, Fla. The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for ...

5. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Durvalumab is FDA approved for treatment in lung cancers including non-small cell lung cancer and small cell lung cancer. Venetoclax is FDA approved for the ...

7. Prophylactic Table ID File.indd

   Page 1.

8. Mayo Clinic Obstetrics and Gynecology Physician Update - November 2024

   Page 1.

9. Cirugía - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to evaluate the safety and feasibility of surgical resection for pre-recurrent brain tumors. Eligible patients with surgically ...

10. Hematología - Ensayos clínicos - Mayo Clinic

    Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia ... However, the FDA has allowed the use of this drug in this research study.